The FDA has approved bimekizumab-bkzx for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Search results for: Bimekizumab
New Indications Possible for Bimekizumab-bkzx
The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab
Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…
Bimekizumab Promising for PsA
CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic…
Bimekizumab Improves Joint & Skin Symptoms in PsA Patients
Preliminary results from an ongoing study show that bimekizumab improves joint and skin symptoms in patients with psoriatic arthritis…
Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…
Approaches to Difficult-to-Manage Spondyloarthritis
At this ACR Convergence 2024 session, two experts spoke about identifying difficult-to-manage patients with spondyloarthritis, differentiating active disease from fibromyalgia & therapy selection in these patients.
Clinical Year in Review: 2023
SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.
From Basic Science to Clinical Treatments: An Update on PsA
Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.